140 related articles for article (PubMed ID: 30416686)
21. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas.
Rambau PF; Duggan MA; Ghatage P; Warfa K; Steed H; Perrier R; Kelemen LE; Köbel M
Histopathology; 2016 Aug; 69(2):288-97. PubMed ID: 26799366
[TBL] [Abstract][Full Text] [Related]
22. Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets.
Kuznetsov VA; Tang Z; Ivshina AV
BMC Genomics; 2017 Oct; 18(Suppl 6):692. PubMed ID: 28984201
[TBL] [Abstract][Full Text] [Related]
23. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
24. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
[TBL] [Abstract][Full Text] [Related]
25. Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Sehouli J; Kunze CA; Dietel M; Braicu I; Letsch A; Darb-Esfahani S
Gynecol Oncol; 2016 Mar; 140(3):494-502. PubMed ID: 26721227
[TBL] [Abstract][Full Text] [Related]
26. Loss/Down-regulation of tumor suppressor in lung cancer 1 expression is associated with tumor progression and is a biomarker of poor prognosis in ovarian carcinoma.
Yang G; He W; Cai M; Luo F; Kung H; Guan X; Zeng Y; Xie D
Int J Gynecol Cancer; 2011 Apr; 21(3):486-93. PubMed ID: 21436696
[TBL] [Abstract][Full Text] [Related]
27. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications.
Köbel M; Kalloger SE; Santos JL; Huntsman DG; Gilks CB; Swenerton KD
Gynecol Oncol; 2010 Jan; 116(1):50-6. PubMed ID: 19822358
[TBL] [Abstract][Full Text] [Related]
28. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas.
Dong Y; Kaushal A; Bui L; Chu S; Fuller PJ; Nicklin J; Samaratunga H; Clements JA
Clin Cancer Res; 2001 Aug; 7(8):2363-71. PubMed ID: 11489814
[TBL] [Abstract][Full Text] [Related]
29. Early stage primary ovarian mucinous carcinoma: Outcome-based clinicopathological study in comparison with serous carcinoma.
Tian Q; Lu B; Ye J; Lu W; Xie X; Wang X
J Int Med Res; 2016 Apr; 44(2):357-66. PubMed ID: 26880793
[TBL] [Abstract][Full Text] [Related]
30. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
[TBL] [Abstract][Full Text] [Related]
31. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
[TBL] [Abstract][Full Text] [Related]
32. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
[TBL] [Abstract][Full Text] [Related]
33. Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma.
Liu FS; Dong JT; Chen JT; Hsieh YT; Ho ES; Hung MJ
Gynecol Oncol; 2000 Jul; 78(1):10-5. PubMed ID: 10873402
[TBL] [Abstract][Full Text] [Related]
34. Emerging role of inhibin as a biomarker for ovarian cancer.
Robertson DM; Oehler MK
Womens Health (Lond); 2005 Jul; 1(1):51-7. PubMed ID: 19803946
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
Karamurzin Y; Leitao MM; Soslow RA
Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
[TBL] [Abstract][Full Text] [Related]
36. UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas.
Berlingieri MT; Pallante P; Guida M; Nappi C; Masciullo V; Scambia G; Ferraro A; Leone V; Sboner A; Barbareschi M; Ferro A; Troncone G; Fusco A
Oncogene; 2007 Mar; 26(14):2136-40. PubMed ID: 17016443
[TBL] [Abstract][Full Text] [Related]
37. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
[TBL] [Abstract][Full Text] [Related]
38. MicroRNAs in Ovarian Cancer.
Katz B; Tropé CG; Reich R; Davidson B
Hum Pathol; 2015 Sep; 46(9):1245-56. PubMed ID: 26216350
[TBL] [Abstract][Full Text] [Related]
39. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma.
Shigemasa K; Hu C; West CM; Clarke J; Parham GP; Parmley TH; Korourian S; Baker VV; O'Brien TJ
J Soc Gynecol Investig; 1997; 4(2):95-102. PubMed ID: 9101469
[TBL] [Abstract][Full Text] [Related]
40. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
Soovares P; Pasanen A; Bützow R; Lassus H
Gynecol Oncol; 2017 Sep; 146(3):615-622. PubMed ID: 28625395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]